Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.45 |
| ▸ | IL1RN | P18510 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11886068 | 0.94 | ACE (0.51) | ACEMMECPA1ACE2OPRD1 | |
| SCHEMBL29857400 | 0.94 | ACE (0.51) | ACEMMECPA1ACE2OPRD1 | |
| SCHEMBL29458786 | 0.94 | ACE (0.51) | ACEMMECPA1ACE2OPRD1 | |
| SCHEMBL29972923 | 0.92 | NAALAD2 (0.53) | ACEMMECPA1ACE2NAALAD2 | |
| SCHEMBL15202798 | 0.90 | ACE (0.51) | ACEMMECPA1ACE2NAALAD2 | |
| SCHEMBL14706288 | 0.87 | NAALAD2 (0.54) | OPRD1NAALAD2IL1RNERAP2 | |
| SCHEMBL30947373 | 0.86 | OPRD1 (0.53) | OPRD1NAALAD2BACE1IL1RNERAP2 | |
| SCHEMBL29378886 | 0.85 | KISS1R (0.56) | OPRD1BACE1KISS1RBACE2 | |
| SCHEMBL18907573 | 0.85 | BACE1 (0.54) | ACEMMECPA1ACE2BACE1 | |
| SCHEMBL31643187 | 0.85 | NAALAD2 (0.55) | ACEMMECPA1ACE2NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | HENKEL AG & CO. KGAA (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20160199281-A1 | HAIR TREATMENT AGENTS CONTAINING OLIGOPEPTIDES AND HYALURONIC ACID ESTERS | HENKEL AG & CO. KGAA (DE) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199281-A1 | HAIR TREATMENT AGENTS CONTAINING OLIGOPEPTIDES AND HYALURONIC ACID ESTERS | CD44, NGLY1, HDGF | ACE 4481/4885MME 541/4885CPA1 455/4885 |
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | SRRM2, PLP2, KRT18 | ACE 4542/4885MME 1779/4885CPA1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.